CD274 and neoplasm: The increased tumor percentage shows that combination treatment with PIK-93 and anti-PDL1 antibodies significantly inhibited tumor growth (P < 0.001; Fig. 7B) and reduced the tumor weight (P = 0.0286; Fig. 7C), compared to anti–PD-L1 antibodies alone.